Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/12/2017
SIETES contiene 92152 citas

 
 
 1 a 20 de 189 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Varga S, Alcusky M, Keith SW, Hegarty SE, Del Canale S, Lombardi M, Maio V. Hospitalization rates during potentially inappropriate medication use in a large population-based cohort of older adults. Br J Clin Pharmacol 2017;83:2572-80. [Ref.ID 102117]
2. Cita con resumen
Alharbi FF, Souverein PC, de Groot MCH, Blom MT, de Boer A, Klungel OH, Tan HL. The impact of serum potassium-influencing antihypertensive drugs on the risk of out-of-hospital cardiac arrest: a case–control study. Br J Clin Pharmacol 2017;83:2541-8. [Ref.ID 102115]
3. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
4.Enlace a cita original Cita con resumen
Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, Mann DL, Margulies KB, NcNulty SE, Mentz RJ, Redfield MM, Tang WHW, Whellan DJ, Shah M, Desvigne-Nickens P, Hernandez AF, Braunwald E, National Heart Lung and Blood Institute Heart Failure Clinical Research Network. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiology 2017:12 de julio. [Ref.ID 101968]
5. Cita con resumen
Pierson-Marchandise M, Gras V, Moragny J, Micallef J, Gaboriau L, Picard S, Choukroun G, Masmoudi K, Liabeuf S, the French National Network of Pharmacovigilance Centres. The drugs that mostly frequently induce acute kidney injury: a case-noncase study of a pharmacovigilance database. Br J Clin Pharmacol 2017;83:1341-9. [Ref.ID 101945]
6. Cita con resumen
Anónimo. Spironolactone - potion or poison?. Drug Ther Bull 2017;55:13. [Ref.ID 101402]
7.Tiene citas relacionadas
Sternlicht H, Bakris GL. Spironolactone for resistant hypertension—hard to resist?. Lancet 2015;386:2032-4. [Ref.ID 99769]
8.Tiene citas relacionadas Cita con resumen
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, for The British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-68. [Ref.ID 99524]
10. Cita con resumen
Warlé-van Herwaarden MF, Valkhoff VE, Herings RMC, Engelkes M, van Blijderveen JC, Rodenburg EM, de Bie S, Alsma J, van de Steeg-Gompel C, Kramers C, Meyboom RHB, Sturkenboom MCJM, De Smet PAGM. Quick assessment of drug-related admissions over time (QUADRAT study). Pharmacoepidemiol Drug Saf 2015;24:495-503. [Ref.ID 98885]
11. Cita con resumen
Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol 2015;151:941-4. [Ref.ID 98866]
12. Cita con resumen
Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN, Canadian Drug Safety and Effectiveness Research Network.. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. Can Med Assoc J 2015;187:E138-143. [Ref.ID 98851]
13. Cita con resumen
Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. Can Med Assoc J 2015;187:E138-43. [Ref.ID 98766]
14.Tiene citas relacionadas Cita con resumen
Hay D, Hill M, Littlewood T. Neutropenia in primary care. BMJ 2014;349:g5340. [Ref.ID 98347]
15. Cita con resumen
Muneer A, Kalsi J, Nazareth I, Arya M. Erectile dysfunction. BMJ 2014;348:g129. [Ref.ID 97218]
16. Cita con resumen
Karimzadeh I, Khalili H, Farsaei S, Dashti-Khavidaki S, Sagheb MM. Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity. Eur J Clin Pharmacol 2013;69:1351-68. [Ref.ID 95849]
17.Tiene citas relacionadas
Edelmann F, Wchter R, Pieske B. Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA 2013;310:205. [Ref.ID 95798]
18.Tiene citas relacionadas
Lund LH, Stáhlberg M. Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA 2013;310:205. [Ref.ID 95797]
19.Tiene citas relacionadas
Millan A, Abram S, Veglio F. Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA 2013;310:204-5. [Ref.ID 95796]
Seleccionar todas
 
 1 a 20 de 189 siguiente >>